P1717: HEALTH-RELATED QUALITY OF LIFE AND TOLERABILITY OF LONCASTUXIMAB TESIRINE IN HIGH-RISK PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED IN A PHASE 2 CLINICAL TRIAL (LOTIS 2)
A. Spira,
L. Liao,
X. Zhou,
A. Gnanasakthy,
L. Chen,
D. Ungar,
E. Yu,
T. Kilavuz,
J. Radford,
M. Hamadani
Affiliations
A. Spira
1 Virginia Cancer Specialists Research Institute, Fairfax, VA
L. Liao
2 ADC Therapeutics America Inc., New Providence, NJ
X. Zhou
3 RTI Health Solutions, Research Triangle Park, NC, United States of America
A. Gnanasakthy
3 RTI Health Solutions, Research Triangle Park, NC, United States of America
L. Chen
2 ADC Therapeutics America Inc., New Providence, NJ
D. Ungar
2 ADC Therapeutics America Inc., New Providence, NJ
E. Yu
2 ADC Therapeutics America Inc., New Providence, NJ
T. Kilavuz
2 ADC Therapeutics America Inc., New Providence, NJ
J. Radford
4 NIHR Clinical Research Facility, the Christie NHS Foundation Trust and University of Manchester, Manchester Academic Health Centre, Manchester, United Kingdom
M. Hamadani
5 Medical College of Wisconsin, Division of Hematology & Oncology, Milwaukee, WI, United States of America
